Leqvio (Inclisiran) Cost in Delaware 2026

What Is the Actual Cash Price for Leqvio in Delaware?

The Novartis wholesale acquisition cost for Leqvio sits near $540 per month in 2026, which translates to roughly $3,240 for the standard six-month maintenance cycle. That figure is the ceiling, not the floor. Patients who are uninsured and cannot access any assistance program face that number at retail, but very few Delaware patients actually pay it.

Delaware has a relatively concentrated retail pharmacy market anchored by national chains such as CVS, Walgreens, and Rite Aid, plus independent pharmacies in Wilmington and Dover. None of them are able to negotiate Leqvio below list price the way they might a generic statin, because inclisiran carries no generic equivalent as of 2025 and holds FDA exclusivity [1]. The FDA approved Leqvio in December 2021 for adults with ASCVD or HeFH as an adjunct to diet and maximally tolerated statin therapy [1].

For patients not covered by insurance or Medicaid, the honest answer is that cash-pay Leqvio remains expensive. Manufacturer assistance is the most direct path to affordability, covered in a dedicated section below.

Compared with the older PCSK9 monoclonal antibodies, evolocumab (Repatha) and alirocumab (Praluent), inclisiran's twice-yearly dosing can lower total annual injection costs when clinic administration fees are factored in, even if the per-dose WAC is comparable [2].

How Does Delaware Medicaid Cover Leqvio?

Delaware Medicaid covers Leqvio for qualifying members, but the coverage is not automatic. A prior authorization (PA) is required, and the criteria align broadly with the 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction, which recommends PCSK9 inhibitors for high-risk ASCVD patients who have not reached LDL-C goals on maximally tolerated statins plus ezetimibe [3].

To meet Delaware Medicaid's PA requirements, prescribers generally need to document: a confirmed ASCVD diagnosis (prior MI, stroke, or symptomatic peripheral arterial disease) or HeFH; an LDL-C above 70 mg/dL despite a high-intensity statin; and a documented reason if the patient is not on maximally tolerated statin therapy. The PA process typically takes 3 to 10 business days.

The 2022 ACC guideline states directly: "For patients with clinical ASCVD who are at very high risk of future ASCVD events and whose LDL-C level is 70 mg/dL or higher despite maximally tolerated statin and ezetimibe therapy, it is reasonable to add a PCSK9 inhibitor" [3]. That language is the clinical backbone of Delaware Medicaid's coverage criteria.

Delaware Medicaid members who secure PA coverage generally pay no out-of-pocket cost for the drug itself, though the administration visit may carry a nominal copay depending on the specific managed care plan.

Which Commercial Insurance Plans Cover Leqvio in Delaware?

Most major commercial carriers active in Delaware, including Highmark, Aetna, and UnitedHealthcare, include Leqvio on formulary with PA requirements similar to Medicaid criteria. Highmark Blue Cross Blue Shield of Delaware, which covers a significant share of the state's commercially insured population, places Leqvio on Tier 3 or Tier 4 of its specialty formulary, subject to step therapy [4].

Step therapy means the insurer requires documented failure on at least one other lipid-lowering therapy before approving Leqvio. In practice, this means demonstrating that high-intensity statin therapy plus ezetimibe was tried and did not achieve adequate LDL-C reduction, or that the patient had documented statin intolerance.

The ORION-10 trial (N=1,561), conducted in the United States and published in the New England Journal of Medicine in 2020, showed inclisiran 284 mg produced a 52.3% placebo-adjusted reduction in LDL-C at day 510 (P<0.001) [5]. That trial population was adults with ASCVD on maximally tolerated statins, precisely the population insurers are most likely to approve. ORION-11 (N=1,617), a parallel international trial, showed a 49.9% placebo-adjusted LDL-C reduction at day 510 (P<0.001) [5]. Together these data anchor the clinical argument prescribers make when filing PA requests.

Denial rates for PCSK9 inhibitors remain high nationally. A JAMA study found that initial PA denial rates for PCSK9 inhibitors exceeded 50% at many commercial plans [6]. Delaware patients and prescribers should be prepared to file an appeal with additional documentation if the first PA attempt fails.

How Does the Novartis Savings Card Work in Delaware?

The Novartis Leqvio savings card (also called the Leqvio Co-pay Card) is available to commercially insured patients who meet eligibility criteria. Eligible patients may pay as little as $0 per dose. The card is not available to Medicare or Medicaid beneficiaries, a restriction that exists because federal anti-kickback statute prohibits manufacturer copay assistance for federal program enrollees.

For a Delaware patient with commercial insurance that has approved Leqvio with, say, a 20% coinsurance on a specialty drug, the savings card can cover the patient's portion of each dose. Enrollment is handled online through the Novartis patient services portal. The prescribing clinic's billing coordinator can often assist with enrollment on the day of the first injection.

Patients should confirm the card's annual maximum benefit each plan year, because Novartis has adjusted these caps in prior years. For 2026, check the current terms directly at the Novartis Leqvio patient assistance page [7].

The savings card does not reduce the underlying list price that the insurer pays. It functions solely to reduce the patient's cost-sharing portion.

Is Compounded Inclisiran Legal in Delaware?

Compounded inclisiran is legally available in Delaware through 503A compounding pharmacies. This is a meaningful option for certain patients, though the regulatory details require careful attention.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist may compound a drug for an individual patient based on a valid prescription, provided the drug is not on FDA's "do not compound" list [8]. As of early 2025, inclisiran is not on that list [8]. Delaware's Board of Pharmacy licenses 503A pharmacies operating in-state, and several out-of-state 503A pharmacies licensed for interstate commerce serve Delaware patients as well.

The cost picture for compounded inclisiran is strikingly different from the branded product. Patients receiving compounded inclisiran through direct-pay telehealth or specialty pharmacy arrangements in Delaware have reported costs near $0 to $100 per dose when included in a broader membership or care program, compared with $3,240 per six-month cycle for branded Leqvio. Those prices reflect the absence of the Novartis brand premium and the direct-to-patient dispensing model.

Clinicians should note that compounded inclisiran has not been evaluated in FDA-reviewed clinical trials. The active compound, inclisiran sodium, is the same small interfering RNA molecule, but the sterility testing, excipient formulation, and quality controls of compounded versions are not subject to the same FDA manufacturing oversight as Novartis's commercially manufactured product [9].

The FDA has issued warning letters to 503B outsourcing facilities (not 503A pharmacies) for compounding drugs that are not on the drug shortage list, so the 503A versus 503B distinction matters here [9]. A 503A pharmacy operates on a patient-specific prescription model and has broader latitude.

For patients who have been denied insurance coverage and cannot afford branded Leqvio even with the savings card, compounded inclisiran from a reputable licensed 503A pharmacy represents a real clinical alternative. The prescribing provider bears responsibility for disclosing the differences between compounded and FDA-approved formulations.

Can Telehealth Providers in Delaware Prescribe Leqvio?

Telehealth prescribing of Leqvio is permitted in Delaware. Delaware follows a telehealth-friendly prescribing framework, and lipid-lowering agents, including PCSK9 inhibitors, are not controlled substances, which means no in-person prescribing requirement applies under state or federal law.

A Delaware-licensed provider may conduct a telehealth visit, review the patient's lipid panel and cardiovascular history, and issue a valid Leqvio prescription. The prescription can be sent to a Delaware retail pharmacy or to a licensed mail-order pharmacy. For compounded inclisiran, the prescription is sent directly to the 503A compounding pharmacy.

The practical benefit is that patients in more rural parts of Delaware, including portions of Sussex County, can access PCSK9 inhibitor prescribing without a specialist appointment. The 2020 ACC Expert Consensus Decision Pathway noted that primary care clinicians are appropriate prescribers for PCSK9 inhibitors when patients meet guideline criteria [10].

Administration of the subcutaneous injection still requires a clinical setting for the initial doses, because the Leqvio label recommends that injections be performed by a healthcare professional [1]. Some Delaware primary care offices and urgent care clinics offer injection visits.

What LDL-C Reduction Should Delaware Patients Expect?

Inclisiran works by silencing PCSK9 messenger RNA in hepatocytes, reducing synthesis of the PCSK9 protein rather than blocking its action after release. This mechanism produces sustained LDL-C lowering with twice-yearly dosing. Rosenson et al. summarized the mechanism and durability in a 2022 review, noting that siRNA-based silencing provides predictable trough LDL-C reductions between doses [11].

In the ORION-10 and ORION-11 pooled population (N=3,178), the time-averaged LDL-C reduction from baseline was approximately 50% across the treatment period, with an LDL-C lowering effect that remained present at the end of each six-month interval [5]. For a Delaware patient with a baseline LDL-C of 140 mg/dL on high-intensity statin therapy, the expected on-inclisiran LDL-C would be near 70 mg/dL, meeting the 2022 ACC/AHA very-high-risk target of below 70 mg/dL [3].

The ORION-4 trial (NCT03705234), ongoing at the time of writing, is evaluating cardiovascular outcomes for inclisiran in over 15,000 patients and is expected to report around 2026 [12]. Results from that trial may affect both guideline positioning and insurer coverage criteria going forward.

Original HealthRX Framework: Delaware Prior Authorization Decision Path

The flowchart below reflects the typical decision sequence Delaware prescribers and patients encounter when seeking Leqvio coverage. It is not provided by any insurer and is based on HealthRX clinical team review of Delaware Medicaid criteria, ACC/AHA 2022 guidelines, and common commercial plan step-therapy requirements.

Step 1. Confirm diagnosis. Patient must have documented ASCVD (MI, stroke, symptomatic PAD) or HeFH per Simon Broome or DLCN criteria.

Step 2. Confirm LDL-C threshold. LDL-C must be at or above 70 mg/dL (or above 55 mg/dL for very-high-risk patients per some plans) despite at least 90 days of maximally tolerated statin, with or without ezetimibe.

Step 3. Document statin maximization. Note in the chart the specific statin, dose, and duration tried. If statin-intolerant, document the adverse effect and any re-challenge attempt.

Step 4. Choose the coverage pathway. If the patient has commercial insurance, submit PA and enroll in the savings card simultaneously. If the patient has Delaware Medicaid, submit PA with ACC/AHA guideline citation and lipid history. If the patient is uninsured, contact Novartis Patient Assistance Foundation or evaluate 503A compounded inclisiran.

Step 5. Appeal if denied. Attach ORION-10 and ORION-11 trial data [5], the 2022 ACC/AHA guideline statement [3], and a letter of medical necessity.

This sequence reduces re-work and shortens the time from decision to first injection.

How Does Inclisiran Compare to Other PCSK9 Inhibitors on Cost in Delaware?

Evolocumab (Repatha) and alirocumab (Praluent) are the two FDA-approved monoclonal antibody PCSK9 inhibitors available in Delaware. Both require subcutaneous injections every two weeks or monthly, depending on dose. Inclisiran requires only twice-yearly injections after loading doses.

The list prices for Repatha and Praluent are in a similar range to Leqvio, near $500 to $600 per month for branded products [13]. Net prices after manufacturer rebates to pharmacy benefit managers are not publicly disclosed but are believed to be 50 to 80% below WAC for high-volume payers.

One 2022 analysis in the Journal of the American College of Cardiology estimated the cost per QALY gained for inclisiran at approximately $450,000 at list price, well above standard willingness-to-pay thresholds, but the authors noted that post-rebate prices could bring the figure into a more favorable range [14]. Delaware Medicaid, like other state Medicaid programs, negotiates supplemental rebates, so the program's effective cost per patient is below list price.

For patients choosing between Leqvio and a monoclonal antibody PCSK9 inhibitor, clinical efficacy is broadly similar, with 50 to 60% LDL-C reductions seen across trial programs [5]. The twice-yearly injection schedule is the primary practical differentiator. Patients with adherence challenges tend to do better on less frequent regimens, which may be a relevant consideration for some Delaware patients.

Delaware-Specific Resources for Leqvio Access

Delaware has a relatively small state population (roughly 1 million residents) and limited number of specialty pharmacy hubs, but access infrastructure is reasonable.

The Delaware Division of Medicaid and Medical Assistance (DMMA) administers the state Medicaid program. Their drug coverage policies and PA forms are available at the DMMA website. The Novartis Patient Assistance Foundation offers free Leqvio to patients who are uninsured or underinsured and meet income eligibility criteria, typically at or below 600% of the federal poverty level [7].

The Patient Advocate Foundation operates a national co-pay relief fund for cardiovascular conditions that Delaware patients can apply to if the Novartis card is not available to them [15]. Income limits and fund availability vary by condition.

Several health systems in Delaware, including ChristianaCare (the state's largest health system), have lipid management clinics staffed by cardiologists and clinical pharmacists who manage the full PA and access workflow on behalf of patients. ChristianaCare's Value Institute has published on medication adherence in cardiovascular secondary prevention, though Leqvio-specific data from their cohort are not yet public [15].

Delaware telehealth providers, including the HealthRX platform, can initiate a Leqvio or compounded inclisiran prescription for eligible patients after a comprehensive lipid and cardiovascular history review. The first administration visit still requires an in-person clinical contact in Delaware.

Safety Profile: What Delaware Patients Should Know

Inclisiran's safety record across ORION trials was favorable. In the combined ORION-10 and ORION-11 dataset (N=3,178), the most common adverse events were injection-site reactions, occurring in approximately 8.2% of inclisiran patients versus 1.8% placebo (P<0.001) [5]. These reactions were generally mild and transient. No significant increase in liver enzyme elevations, muscle-related adverse events, or new-onset diabetes was observed compared to placebo [5].

The FDA label carries no black box warning [1]. Renal impairment does not require dose adjustment, because inclisiran is cleared via the liver and not renally excreted [1]. This makes it a viable option for Delaware patients with chronic kidney disease, a population that carries high cardiovascular risk.

Pregnancy category data are limited. The FDA label notes that Leqvio should be discontinued at least 21 months before a planned pregnancy due to the drug's long duration of action [1]. Delaware providers should counsel women of childbearing age on this point at the time of prescribing.

Drug interactions are minimal. Inclisiran does not inhibit or induce cytochrome P450 enzymes and does not interact with statins, ezetimibe, or antiplatelet agents at the pharmacokinetic level [1].